DGAP-News Competitive Technologies´ Calmare Therapy Treatment Medical Device Decreases Pain In Cancer Patients, Study Shows

Competitive Technologies, Inc. /

08.09.2010 21:00

---

FAIRFIELD, Conn., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies,
Inc. (OTCQB:CTTC) announced today the publication of the detailed results from
a study that shows the successful treatment of patients suffering from pain
associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC´s
Calmare(r) Pain Therapy Treatment. The article published in the Journal of Pain
and Symptom Management (www.jpsmjournal.com), detailed the study led by
principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care
Research and Medical Director of the Thomas Palliative Care Unit Virginia
Commonwealth University´s Massey Cancer Center.

Calmare, which treats chronic neuropathic and oncologic pain, received FDA
certification for sales in the U.S. in 2009. In June 2009, clinical
investigators at the VCU Massey Cancer Center began the first U.S. independent
clinical study, to specifically examine the ability of CTTC´s Calmare pain
therapy treatment to decrease pain associated with CIPN.

´The Massey Cancer Center team, led by Dr. Smith, was the first independent
group in the U.S. to conduct its own evidence-based study using the Calmare
pain therapy device to treat CIPN in cancer patients. CIPN is a very
debilitating side effect for some 30-40 percent of cancer patients, causing
sharp pain in their hands and feet. CIPN affects cancer patients worldwide,
including an estimated 4 million cancer patients in the U.S. Calmare pain
therapy is the only highly effective treatment for CIPN without the harmful,
adverse side effects of opioids, ´ said Johnnie Johnson, Competitive
Technologies´ interim CEO.

´We are proud of the patient outcomes achieved with this breakthrough treatment
in the clinical research study at VCU Massey Cancer Center, a National Cancer
Institute-designated center that helps lead our nation´s cancer research
agenda, ´ said Aris D. Despo, CTTC´s Executive VP, Business Development. ´We are
excited about the investigators´ success using Calmare in treating pain. This
research confirms our approach to providing a solution to the needs of cancer
patients and to improving palliative healthcare globally.´

Calmare is being used to treat international patients in Italy, India, Greece,
Bangladesh, and U.S. patients at clinics in Utah, Texas, Massachusetts, New
York, Virginia, Florida, Connecticut and Rhode Island.  In addition to treating
pain associated with cancer and cancer treatments, Calmare Pain Therapy also
successfully treats chronic neuropathic pain resulting from shingles, failed
back surgery, phantom limb syndrome, sciatica, spinal stenosis and other
maladies.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, provides distribution, patent
and technology transfer, sales and licensing services focused on the needs of
its customers and matching those requirements with commercially viable product
or technology solutions. CTTC is a global leader in identifying, developing and
commercializing innovative products and technologies in life, electronic, nano,
and physical sciences developed by universities, companies and inventors. CTTC
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTTC´s website: www.competitivetech.net.

The non-invasive Calmare(r) pain therapy device uses the biophysical ´Scrambler
Therapy´ technology, which was developed in Italy by CTTC´s client, Professor
Giuseppe Marineo. CTTC´s partner, GEOMC Co. Ltd. of Seoul, Korea is
manufacturing the Calmare device, which has U.S. FDA clearance and European
Union CE Mark clearance for sales. For more information about Calmare Pain
Therapy Treatment, visit www.CalmareTT.com.
Statements made about our future expectations are forward-looking statements
and subject to risks and uncertainties as described in our most recent Annual
Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on
October 27, 2009, and other filings with the SEC, and are subject to change at
any time. Our actual results could differ materially from these forward-looking
statements. We undertake no obligation to update publicly any forward-looking
statement.

CONTACT:  IR Services, LLC
          Jean Wilczynski
          860.434.2465
          jdjohnson@corpirservices.com

News Source: NASDAQ OMX

08.09.2010 21:00 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language:     English
Company:      Competitive Technologies, Inc.
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US2045121074
WKN:          

End of Announcement                             DGAP News-Service

---

Bewerten Sie diesen Artikel: (

0

Bewertungen)